3,3′-Diindolylmethane improves antitumor immune responses of PD-1 blockade via inhibiting myeloid-derived suppressor cells

[1] Taylor A(2018)Small-molecule inhibition of PD-1 transcription is an effective alternative to antibody blockade in cancer therapy Cancer Res 78 706-17

[2] Rothstein D(2013)Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors Cancer Res 73 3591-603

[3] Rudd CE(2016)PI3Kgamma is a molecular switch that controls immune suppression Nature 539 437-42

[4] Binder DC(2019)Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients Oncoimmunology 8 e1564505-79

[5] Schreiber H(2019)Treg-mediated acquired resistance to immune checkpoint inhibitors Cancer Lett 457 168-86

[6] Kaneda MM(2020)A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy J Clin Invest 130 2570-7

[7] Messer KS(2019)The most important cell you have never heard of MDSC Trends Pharmacol Sci 40 4-20

[8] Ralainirina N(2016)The nature of myeloid-derived suppressor cells in the tumor microenvironment Trends Immunol 37 208-9

[9] Limagne E(2014)Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells Proc Natl Acad Sci U S A 111 11774-64

[10] Richard C(2015)Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected J Clin Invest 125 3356-58

[1] Taylor A(2018)Small-molecule inhibition of PD-1 transcription is an effective alternative to antibody blockade in cancer therapy Cancer Res 78 706-17

[2] Rothstein D(2013)Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors Cancer Res 73 3591-603

[3] Rudd CE(2016)PI3Kgamma is a molecular switch that controls immune suppression Nature 539 437-42

[4] Binder DC(2019)Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients Oncoimmunology 8 e1564505-79

[5] Schreiber H(2019)Treg-mediated acquired resistance to immune checkpoint inhibitors Cancer Lett 457 168-86

[6] Kaneda MM(2020)A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy J Clin Invest 130 2570-7

[7] Messer KS(2019)The most important cell you have never heard of MDSC Trends Pharmacol Sci 40 4-20

[8] Ralainirina N(2016)The nature of myeloid-derived suppressor cells in the tumor microenvironment Trends Immunol 37 208-9

[9] Limagne E(2014)Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells Proc Natl Acad Sci U S A 111 11774-64

[10] Richard C(2015)Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected J Clin Invest 125 3356-58